Published in Clin Exp Metastasis on January 01, 2004
Non-classical p38 map kinase functions: cell cycle checkpoints and survival. Int J Biol Sci (2008) 2.18
Role of p38 MAP Kinase Signal Transduction in Solid Tumors. Genes Cancer (2013) 1.73
TGF-β1 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1/2 in highly invasive breast cancer cells. BMC Cancer (2012) 1.27
ETS-1 protein regulates vascular endothelial growth factor-induced matrix metalloproteinase-9 and matrix metalloproteinase-13 expression in human ovarian carcinoma cell line SKOV-3. J Biol Chem (2012) 1.19
Acid beta-glucosidase 1 counteracts p38delta-dependent induction of interleukin-6: possible role for ceramide as an anti-inflammatory lipid. J Biol Chem (2009) 1.10
p38α MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance. World J Gastroenterol (2014) 1.02
TAK1-TAB2 signaling contributes to bone destruction by breast carcinoma cells. Mol Cancer Res (2011) 0.90
Basement membrane dissolution and reassembly by limbal corneal epithelial cells expanded on amniotic membrane. Invest Ophthalmol Vis Sci (2006) 0.86
MAPK11 in breast cancer cells enhances osteoclastogenesis and bone resorption. Biochimie (2014) 0.80
Heparanase promotes human gastric cancer cells migration and invasion by increasing Src and p38 phosphorylation expression. Int J Clin Exp Pathol (2014) 0.79
Matrix-metalloproteinase-9 is cleaved and activated by cathepsin K. BMC Res Notes (2015) 0.79
Blockade of Ets-1 attenuates epidermal growth factor-dependent collagen loss in human carotid plaque smooth muscle cells. Am J Physiol Heart Circ Physiol (2015) 0.78
SENP5 mediates breast cancer invasion via a TGFβRI SUMOylation cascade. Oncotarget (2014) 0.78
Tumor cell p38 MAPK: A trigger of cancer bone osteolysis. Cancer Cell Microenviron (2015) 0.78
Tumor microenvironment regulates metastasis and metastasis genes of mouse MMTV-PymT mammary cancer cells in vivo. Vet Pathol (2013) 0.77
What Is Breast in the Bone? Int J Mol Sci (2016) 0.75
Tumor p38MAPK signaling enhances breast carcinoma vascularization and growth by promoting expression and deposition of pro-tumorigenic factors. Oncotarget (2017) 0.75
Involvement of chemokine receptors in breast cancer metastasis. Nature (2001) 26.07
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer (2002) 17.49
A multigenic program mediating breast cancer metastasis to bone. Cancer Cell (2003) 16.86
A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science (1994) 10.99
Skeletal complications of malignancy. Cancer (1997) 5.41
IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol (2003) 4.64
TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J (2002) 3.80
Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest (1996) 3.44
p38 MAP kinases: beyond the stress response. Trends Biochem Sci (2000) 3.20
Beta-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation. J Biol Chem (2002) 2.67
A murine model of experimental metastasis to bone and bone marrow. Cancer Res (1988) 2.32
TGF beta-1 regulation of VEGF production by breast cancer cells. Ann Surg Oncol (1997) 1.63
Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-kappa B ligand signaling. J Biol Chem (2002) 1.59
Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer (2003) 1.58
Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res (1999) 1.43
p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells. Cancer Res (2003) 1.40
Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett (2003) 1.39
Relationship of bone destruction in skeletal metastases to osteoclast activation and prostaglandins. Nature (1976) 1.39
Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity. J Biol Chem (2000) 1.38
Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer (2000) 1.35
Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res (2002) 1.33
Transforming growth factor-beta1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity. Int J Cancer (1998) 1.27
The p38 MAPK pathway is required for cell growth inhibition of human breast cancer cells in response to activin. J Biol Chem (2001) 1.22
Mutation rate of MAP2K4/MKK4 in breast carcinoma. Hum Mutat (2002) 1.21
Platelet-derived growth factor activates p38 mitogen-activated protein kinase through a Ras-dependent pathway that is important for actin reorganization and cell migration. J Biol Chem (1999) 1.19
p38 isoforms have opposite effects on AP-1-dependent transcription through regulation of c-Jun. The determinant roles of the isoforms in the p38 MAPK signal specificity. J Biol Chem (2002) 1.19
Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-beta 1. A critical role of p38/nuclear factor-kappa B signaling pathway. J Biol Chem (2002) 1.18
The skeleton as a unique environment for breast cancer cells. Clin Exp Metastasis (2003) 1.17
Rac1-MKK3-p38-MAPKAPK2 pathway promotes urokinase plasminogen activator mRNA stability in invasive breast cancer cells. J Biol Chem (2002) 1.13
The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. Med Res Rev (2001) 1.13
Smad3 mediates transforming growth factor-beta-induced collagenase-3 (matrix metalloproteinase-13) expression in human gingival fibroblasts. Evidence for cross-talk between Smad3 and p38 signaling pathways. J Biol Chem (2002) 1.11
Transforming growth factor beta1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells. Clin Exp Metastasis (1999) 1.10
Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment. Breast Cancer Res (2003) 1.07
Expression of membrane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay. Cancer Res (1996) 1.03
Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res (2001) 1.00
Activation of the p38 mitogen-activated protein kinase pathway by estrogen or by 4-hydroxytamoxifen is coupled to estrogen receptor-induced apoptosis. J Biol Chem (2000) 1.00
Up-regulation of vascular endothelial growth factor in breast cancer cells by the heregulin-beta1-activated p38 signaling pathway enhances endothelial cell migration. Cancer Res (2001) 1.00
Expression of human collagenase-3 (MMP-13) by fetal skin fibroblasts is induced by transforming growth factor beta via p38 mitogen-activated protein kinase. FASEB J (2001) 0.98
A matrix metalloproteinase inhibitor, batimastat, retards the development of osteolytic bone metastases by MDA-MB-231 human breast cancer cells in Balb C nu/nu mice. Eur J Cancer (2001) 0.96
Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases. Breast Cancer Res Treat (2000) 0.95
Alpha(v) integrin, p38 mitogen-activated protein kinase, and urokinase plasminogen activator are functionally linked in invasive breast cancer cells. J Biol Chem (2001) 0.93
Arterial microvascularization and breast cancer colonization in bone. Histol Histopathol (1997) 0.88
Inhibition of fibroblast-induced angiogenic phenotype of cultured endothelial cells by the overexpression of tissue inhibitor of metalloproteinase (TIMP)-3. J Biomed Sci (2003) 0.83
p38MAPK induces cell surface alpha4 integrin downregulation to facilitate erbB-2-mediated invasion. Neoplasia (2003) 0.81
Tumor necrosis factor-alpha induces interleukin-6 production via extracellular-regulated kinase 1 activation in breast cancer cells. Breast Cancer Res Treat (2003) 0.81
Transcriptional activation of collagenase-3 by transforming growth factor-beta1 is via MAPK and Smad pathways in human breast cancer cells. FEBS Lett (2002) 0.80
Human breast cancer cells induced angiogenesis, recruitment, and activation of osteoclasts in osteolytic metastasis. J Cancer Res Clin Oncol (2000) 0.77
Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem (2002) 1.95
Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res (2006) 1.69
Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma. Mol Imaging Biol (2013) 1.67
Patient-perceived and objective functional outcomes following transoral robotic surgery for early oropharyngeal carcinoma. Arch Otolaryngol Head Neck Surg (2011) 1.62
Pretreatment, preoperative swallowing exercises may improve dysphagia quality of life. Laryngoscope (2006) 1.59
Stereomicroscopic fluorescence imaging of head and neck cancer xenografts targeting CD147. Cancer Biol Ther (2008) 1.57
Robotic-assisted surgery for primary or recurrent oropharyngeal carcinoma. Arch Otolaryngol Head Neck Surg (2010) 1.52
Serum osteocalcin is not associated with glucose but is inversely associated with leptin across generations of nondiabetic women. J Clin Endocrinol Metab (2012) 1.49
Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res (2002) 1.46
Dynasplint for the management of trismus after treatment of upper aerodigestive tract cancer: a retrospective study. Ear Nose Throat J (2011) 1.45
Fluorescent labeled anti-EGFR antibody for identification of regional and distant metastasis in a preclinical xenograft model. Head Neck (2008) 1.42
Utility of CT surveillance for primary site recurrence of squamous cell carcinoma of the head and neck. Head Neck (2010) 1.39
Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol (2002) 1.38
Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate (2007) 1.37
Isolated primary osteocytes express functional gap junctions in vitro. Cell Tissue Res (2005) 1.36
Sensitivity and specificity of fluorescent immunoguided neoplasm detection in head and neck cancer xenografts. Arch Otolaryngol Head Neck Surg (2007) 1.33
Use of panitumumab-IRDye800 to image microscopic head and neck cancer in an orthotopic surgical model. Ann Surg Oncol (2012) 1.30
Functional outcomes after transoral robotic surgery for head and neck cancer. Otolaryngol Head Neck Surg (2009) 1.29
Conditioned medium from osteocytes stimulates the proliferation of bone marrow mesenchymal stem cells and their differentiation into osteoblasts. Exp Cell Res (2004) 1.28
Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin Lab (2006) 1.22
Osteocytes inhibit osteoclastic bone resorption through transforming growth factor-beta: enhancement by estrogen. J Cell Biochem (2002) 1.22
Inhibition of gp130 signaling in breast cancer blocks constitutive activation of Stat3 and inhibits in vivo malignancy. Cancer Res (2004) 1.20
Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion. Mol Cancer Res (2008) 1.18
The role of free tissue transfer in the reconstruction of massive neglected skin cancers of the head and neck. Arch Facial Plast Surg (2003) 1.17
Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). Clin Chem (2004) 1.17
Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res (2003) 1.16
Fibroblast-derived MT1-MMP promotes tumor progression in vitro and in vivo. BMC Cancer (2006) 1.16
Fluorescently labeled cetuximab to evaluate head and neck cancer response to treatment. Cancer Biol Ther (2007) 1.16
Free tissue transfer to manage salvage laryngectomy defects after organ preservation failure. Laryngoscope (2007) 1.16
Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer. Clin Cancer Res (2009) 1.16
Intracellular machinery for matrix degradation in bone-resorbing osteoclasts. J Bone Miner Res (2004) 1.15
An essential role for gp130 in neointima formation following arterial injury. Circ Res (2007) 1.15
Osteoclast ruffled border has distinct subdomains for secretion and degraded matrix uptake. Traffic (2003) 1.14
The critical role of IL-34 in osteoclastogenesis. PLoS One (2011) 1.14
FGF-8 is involved in bone metastasis of prostate cancer. Int J Cancer (2008) 1.13
Intracellular membrane trafficking in bone resorbing osteoclasts. Microsc Res Tech (2003) 1.13
Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J Bone Miner Res (2005) 1.12
Associations between homocysteine, bone turnover, BMD, mortality, and fracture risk in elderly women. J Bone Miner Res (2007) 1.11
Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitro. J Biol Chem (2004) 1.11
Death of osteocytes turns off the inhibition of osteoclasts and triggers local bone resorption. Biochem Biophys Res Commun (2005) 1.11
Transoral robotic-assisted surgery for head and neck squamous cell carcinoma: one- and 2-year survival analysis. Arch Otolaryngol Head Neck Surg (2010) 1.10
Assessment and incidence of salivary leak following laryngectomy. Laryngoscope (2012) 1.10
Disruption of the AKT pathway inhibits metastasis in an orthotopic model of head and neck squamous cell carcinoma. Laryngoscope (2011) 1.09
IND-directed safety and biodistribution study of intravenously injected cetuximab-IRDye800 in cynomolgus macaques. Mol Imaging Biol (2015) 1.08
Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors. Prostate (2010) 1.08
Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss. Prostate (2009) 1.06
Toll-like receptor 9 is a novel biomarker for esophageal squamous cell dysplasia and squamous cell carcinoma progression. J Innate Immun (2011) 1.06
Monocyte-macrophage system as a target for estrogen and selective estrogen receptor modulators. Ann N Y Acad Sci (2006) 1.06
Fluorescently labeled therapeutic antibodies for detection of microscopic melanoma. Laryngoscope (2013) 1.04
Possible role of direct Rac1-Rab7 interaction in ruffled border formation of osteoclasts. J Biol Chem (2005) 1.01
Assessment of indocyanine green-labeled cetuximab to detect xenografted head and neck cancer cell lines. Otolaryngol Head Neck Surg (2007) 1.00
Increased Toll-like receptor 9 expression indicates adverse prognosis in oesophageal adenocarcinoma. Histopathology (2011) 0.99
Bone turnover markers and prediction of fracture: a prospective follow-up study of 1040 elderly women for a mean of 9 years. J Bone Miner Res (2010) 0.99
Estrogen receptor-α and sex steroid hormones regulate Toll-like receptor-9 expression and invasive function in human breast cancer cells. Breast Cancer Res Treat (2011) 0.98
Toll-like receptor-9 expression is inversely correlated with estrogen receptor status in breast cancer. J Innate Immun (2008) 0.98
Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer. Breast Cancer Res Treat (2012) 0.98
Membrane-bound carbonic anhydrases in osteoclasts. Bone (2006) 0.98
Short DNA sequences and bacterial DNA induce esophageal, gastric, and colorectal cancer cell invasion. APMIS (2012) 0.98
Absent Toll-like receptor-9 expression predicts poor prognosis in renal cell carcinoma. J Exp Clin Cancer Res (2011) 0.98
Use of panitumumab-IRDye800 to image cutaneous head and neck cancer in mice. Otolaryngol Head Neck Surg (2013) 0.97
Outcomes of salvage surgery with free flap reconstruction for recurrent oral and oropharyngeal cancer. Laryngoscope (2010) 0.97
Bone marrow cell differentiation induced by mechanically damaged osteocytes in 3D gel-embedded culture. J Bone Miner Res (2006) 0.97
(18)F-FDG PET/CT imaging detects therapy efficacy of anti-EMMPRIN antibody and gemcitabine in orthotopic pancreatic tumor xenografts. Mol Imaging Biol (2012) 0.96
Human mesenchymal stem cell derived osteoblasts degrade organic bone matrix in vitro by matrix metalloproteinases. Matrix Biol (2005) 0.96
Serial assessment of serum bone metabolism markers identifies women with the highest rate of bone loss and osteoporosis risk. J Clin Endocrinol Metab (2008) 0.95
Incidence and outcomes of stricture formation postlaryngectomy. Otolaryngol Head Neck Surg (2011) 0.95
Expandable tracheal stenting for benign disease: worth the complications? Ann Otol Rhinol Laryngol (2006) 0.94
Closure of post-laryngectomy pharyngocutaneous fistulae. Head Neck Oncol (2011) 0.94
Outcomes following temporal bone resection. Laryngoscope (2010) 0.93
EGFR expression in advanced head and neck cutaneous squamous cell carcinoma. Head Neck (2011) 0.93
Biochemical markers of bone turnover are influenced by recently sustained fracture. Bone (2005) 0.93
Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res (2005) 0.93
Optical imaging predicts tumor response to anti-EGFR therapy. Cancer Biol Ther (2010) 0.93
Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia. Blood (2011) 0.93
Identification of the optimal therapeutic antibody for fluorescent imaging of cutaneous squamous cell carcinoma. Cancer Biol Ther (2013) 0.92
Intracellular membrane trafficking pathways in bone-resorbing osteoclasts revealed by cloning and subcellular localization studies of small GTP-binding rab proteins. Biochem Biophys Res Commun (2002) 0.92
Regulation of osteoblast differentiation: a novel function for fibroblast growth factor 8. Endocrinology (2006) 0.92
Modulation of tumor cell growth in vivo by extracellular matrix metalloprotease inducer. Arch Otolaryngol Head Neck Surg (2008) 0.92
Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo. Clin Cancer Res (2006) 0.92
Free flap reconstruction of lateral mandibular defects: indications and outcomes. Otolaryngol Head Neck Surg (2011) 0.91
Estrogen responsiveness of bone formation in vitro and altered bone phenotype in aged estrogen receptor-alpha-deficient male and female mice. Eur J Endocrinol (2005) 0.91
Association between human papilloma virus/Epstein-Barr virus coinfection and oral carcinogenesis. J Oral Pathol Med (2014) 0.91
Evidence for the role of osteocytes in the initiation of targeted remodeling. Technol Health Care (2009) 0.91
Receptor tyrosine kinase inhibition causes simultaneous bone loss and excess bone formation within growing bone in rats. Toxicol Appl Pharmacol (2011) 0.91
Fibroblast growth factor receptor mediates fibroblast-dependent growth in EMMPRIN-depleted head and neck cancer tumor cells. Mol Cancer Res (2011) 0.91
Transient 100 nM dexamethasone treatment reduces inter- and intraindividual variations in osteoblastic differentiation of bone marrow-derived human mesenchymal stem cells. Tissue Eng Part C Methods (2012) 0.91
Anti-EMMPRIN antibody treatment of head and neck squamous cell carcinoma in an ex-vivo model. Anticancer Drugs (2010) 0.91
Robot-assisted surgery for upper aerodigestive tract neoplasms. Arch Otolaryngol Head Neck Surg (2009) 0.90